Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

Targeted therapies have changed the landscape of treatments for non-small cell lung cancer (NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring genetic alterations in four oncogenes, and agents targeting additional oncogenic drivers are under investigation. Standard f...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacology & therapeutics (Oxford) 2019-01, Vol.193, p.20-30
Main Authors: Yoda, Satoshi, Dagogo-Jack, Ibiayi, Hata, Aaron N.
Format: Article
Language:English
Subjects:
ALK
Anaplastic Lymphoma Kinase - genetics
Animals
BRAF
Carcinogenesis
EGFR
ErbB Receptors - genetics
Humans
Immunotherapy
Lung Neoplasms - genetics
Lung Neoplasms - therapy
Molecular Targeted Therapy
NSCLC
Proto-Oncogene Proteins
ROS1
Targeted therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Targeted therapies have changed the landscape of treatments for non-small cell lung cancer (NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring genetic alterations in four oncogenes, and agents targeting additional oncogenic drivers are under investigation. Standard first-line chemotherapy has been supplanted by these targeted therapies due to superior efficacy and lower toxicity. Despite excellent response rates and durable responses in some cases, most patients experience relapse within a few years due to the development of acquired drug resistance. Next generation targeted therapies are being developed to overcome drug resistance and extend the duration of therapy. In this review, we summarize the current treatment strategies for the major targetable oncogenic mutations/alterations in NSCLC and discuss the mechanisms leading to acquired drug resistance.
ISSN:0163-7258
1879-016X
DOI:10.1016/j.pharmthera.2018.08.007